ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes.

Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan YP, Soula O, DeVries JH

Diabetes, obesity & metabolism18 Jan 2021Cited by 21 (Europe PMC)

PMID33336850DOI10.1111/dom.14302PepBankPUB-33336850

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

01HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome
In type 1 diabetes, ADO09 reduced first-hour postprandial glucose excursions by more than 95% versus lispro.
In plain wordsIn type 1 diabetes, the insulin-pramlintide formulation reduced first-hour glucose excursions more than lispro.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseFirst-hour postprandial glucose excursions
Study
n = 24
Comparator
Insulin lispro
Outcome group
Glycemic control · Metabolic and weight
Measurements
ΔAUC BG 0-1 h
1.4 mg*h/dL
ADO09
ΔAUC BG 0-1 h
43.5 mg*h/dL
Lispro
Reduction in postprandial blood glucose excursion versus Lispro
> 95%
first hour postmeal
Source sentences
Summary
Compared with Lispro, ADO09 reduced postprandial blood glucose (ppBG) excursions by more than 95% in the first hour postmeal (mean ± SD ∆AUC BG 0-1 h: 1.4 ± 9.9 mg*h/dL vs. 43.5 ± 15.3 mg*h/dL; p < .0001).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Summary · context
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3333685001
02HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome
In type 1 diabetes, ADO09 reduced maximum postprandial glucose versus lispro.
In plain wordsIn type 1 diabetes, the insulin-pramlintide formulation reduced peak glucose more than lispro.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMaximum postprandial glucose
Study
n = 24
Comparator
Insulin lispro
Outcome group
Glycemic control · Metabolic and weight
Measurements
ΔBGmax
87 mg/dL
ADO09
ΔBGmax
109.2 mg/dL
Lispro
Source sentences
Summary
Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Summary · context
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3333685002
03HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome
In type 1 diabetes, ADO09 reduced maximum postprandial glucose versus separate insulin and pramlintide injections.
In plain wordsIn type 1 diabetes, ADO09 reduced peak glucose more than separate insulin and pramlintide injections.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseMaximum postprandial glucose
Study
n = 24
Comparator
Separate human insulin and pramlintide injections
Outcome group
Glycemic control · Metabolic and weight
Measurements
ΔBGmax
87 mg/dL
ADO09
ΔBGmax
109.4 mg/dL
Ins&Pram
Source sentences
Summary
Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Summary · context
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3333685003
04HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome
In type 1 diabetes, gastric emptying with ADO09 was similar to separate insulin and pramlintide injections.
In plain wordsIn type 1 diabetes, ADO09 and separate insulin-pramlintide injections had similar effects on stomach emptying.
Peptide
Pramlintide (Symlin)
Outcome
No significant changeGastric emptying
Study
n = 24
Comparator
Separate human insulin and pramlintide injections
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
Gastric emptying with ADO09 was similar to Ins&Pram and significantly slower than with Lispro.
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Summary · context
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3333685004
05HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialEfficacy outcome
In type 1 diabetes, gastric emptying was slower with ADO09 than with lispro.
In plain wordsIn type 1 diabetes, ADO09 slowed stomach emptying more than lispro.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGastric emptying
Study
n = 24
Comparator
Insulin lispro
Outcome group
Gastrointestinal motility · Gastrointestinal
Source sentences
Summary
Gastric emptying with ADO09 was similar to Ins&Pram and significantly slower than with Lispro.
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Summary · context
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3333685005
06HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialSafety outcome
In type 1 diabetes, adverse events were rare during meal tests with ADO09, insulin-pramlintide injections, and lispro.
In plain wordsIn type 1 diabetes, adverse events were rare during meal tests with all treatments.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedAdverse events
Study
n = 24
Outcome group
Adverse events · Whole body
Source sentences
Summary
All treatments were well tolerated and both adverse events and hypoglycaemic events were rare during the meal test procedure.
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Summary · context
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3333685006
07HumanNot a test of Pramlintide (Symlin) aloneNon-randomized trialSafety outcome
In type 1 diabetes, hypoglycaemic events were rare during meal tests with ADO09, insulin-pramlintide injections, and lispro.
In plain wordsIn type 1 diabetes, low glucose events were rare during meal tests with all treatments.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedHypoglycaemic events
Study
n = 24
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
All treatments were well tolerated and both adverse events and hypoglycaemic events were rare during the meal test procedure.
2 context sentences(design, population, supporting numbers)
Summary · context
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Summary · context
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-3333685007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.